Wasatch BioLabs has announced a co-marketing agreement with Agilent Technologies to expand access to its Direct Targeted Methylation Sequencing (dTMS) platform. The partnership integrates Agilent’s SureSelect and Avida enrichment chemistries with Wasatch BioLabs’ Oxford Nanopore-based native-read workflow, aiming to streamline high-throughput targeted sequencing for research use only (RUO) and translational settings.
The announcement marks a notable shift in how researchers and developers might approach multi-omic biomarker analysis, especially for applications in liquid biopsy, rare disease, neurology, and oncology. By focusing on preserving native DNA features while eliminating common biases associated with bisulfite and PCR-based methods, the dTMS platform is being positioned not just as an incremental improvement—but as a foundational rethinking of scalable sequencing workflows.
What this reveals about the changing expectations in precision multi-omics
The Wasatch BioLabs and Agilent collaboration underscores a growing demand for high-fidelity, application-specific sequencing that is both scalable and translationally relevant. This deal is not just a technical bundling of reagents and hardware; it reflects the deeper shift toward “native-read” sequencing, where preserving epigenetic and structural signatures is becoming critical in emerging areas like methylation profiling and structural variant detection.
Industry observers suggest that research groups increasingly want more than raw sequencing data—they are seeking interpretability, consistency, and the ability to connect genetic and epigenetic variation across the same reads. While short-read technologies have dominated mainstream sequencing for over a decade, they fall short in delivering this level of biological resolution. The dTMS platform, as described, addresses this gap by integrating targeted enrichment and long-read technologies in a streamlined, service-accessible format.
This may help push native-read sequencing beyond niche adoption into broader translational programs, particularly those designing next-generation liquid biopsy assays, cell-free DNA screens, and rare variant detection in population-scale cohorts.
Why eliminating bisulfite and PCR artifacts matters for research translation
The core pitch of dTMS lies in its ability to capture DNA methylation, structural variants, and allelic context without resorting to bisulfite conversion or PCR amplification. These two legacy steps—while effective in traditional sequencing workflows—introduce well-known distortions: bisulfite conversion can damage DNA and erase base-level features, while PCR tends to bias results by over-representing certain sequences and masking native methylation signals.
Clinicians and translational researchers working in early detection, such as liquid biopsy, have been pushing for methodologies that allow accurate, repeatable capture of multiple biomarkers from minimal input. Wasatch BioLabs’ approach could serve that demand by preserving native DNA structure and methylation patterns across both short and long genomic targets—essential for resolving complex variations like repeat expansions, gene fusions, and epigenetic switching events.
For programs working with limited or degraded samples (e.g., circulating cell-free DNA), this shift may be especially consequential. The potential to achieve single-assay multi-omic readouts, with lower error profiles, is expected to reduce the number of false negatives and improve diagnostic resolution in early disease detection efforts.
How the native-read workflow compares with other targeted NGS platforms
Unlike short-read panels offered by companies such as Illumina, Thermo Fisher Scientific, or Roche, the Wasatch BioLabs platform focuses on native DNA without fragmentation or amplification. While traditional platforms prioritize speed and cost-efficiency at scale, they often compromise on the ability to resolve long-range structural and epigenetic features in a single read.
By contrast, Wasatch BioLabs is leveraging Oxford Nanopore Technologies’ long-read sequencing capabilities to provide both base-level and structural insight in a single workflow. Paired with Agilent’s SureSelect and Avida chemistries, which enable hybrid capture-based targeting of up to 1 megabase regions, the combined workflow offers an enriched view of native DNA with relatively low off-target noise and higher customization.
Researchers working with repeat-rich regions, hybrid alleles, or subtelomeric zones, which are often poorly served by traditional short-read methods, may find this workflow more suitable. The question is whether this higher analytical fidelity can be consistently achieved at the scale and turnaround times demanded by larger studies or regulated environments.
What the early access period could signal for clinical pipeline development
The dTMS service is currently in early access, with full availability expected post-Q1 2026. According to Wasatch BioLabs, early adopters include programs in oncology, rare disease, neurology, and prenatal research—therapeutic areas where genomic and epigenomic interactions often underlie disease etiology.
Industry observers believe that this trial phase could serve as a proving ground for future assay development, especially if early partners can demonstrate reproducible clinical utility across multi-site or multi-cohort studies. If successful, this could pave the way for a regulatory pathway, likely through Laboratory Developed Tests or premarket submissions, by 2027.
Still, whether the workflow can meet the stringent requirements of clinical labs, such as CLIA certification and FDA expectations for diagnostic assays, remains an open question. Agilent’s involvement may add credibility, especially through its established channels in diagnostics and regulatory-compliant reagent manufacturing.
What scalability and reproducibility challenges remain
The technical proposition is compelling, but several execution risks must be considered. Scalability will hinge on Wasatch BioLabs’ ability to deliver consistent performance across high-throughput runs without batch effects or readout variability. Given that Oxford Nanopore–based systems are still evolving in terms of consensus accuracy and standardization, downstream bioinformatics and pipeline validation will be critical.
Moreover, while Agilent’s hybrid-capture kits are known for reproducibility, the integration with a native-read platform may require adjustments in hybridization conditions and fragmentation profiles. This could lead to unforeseen compatibility issues when transitioning from research use to regulated deployment.
Another potential bottleneck is interpretation. With native-read multi-omics, data dimensionality increases significantly. If Wasatch BioLabs intends to move toward clinical translation, it must ensure that its informatics stack is capable of delivering clear, actionable reports to clinicians and regulators without oversimplifying the signal complexity that gives the technology its edge.
How the Agilent partnership enhances channel reach and validation credibility
Agilent Technologies brings a well-established ecosystem of laboratory customers, regulatory expertise, and operational scale to the table. While Wasatch BioLabs has carved out a focused niche in long-read sequencing services, its go-to-market footprint has so far been limited to specialized research partnerships.
The co-marketing arrangement allows Wasatch BioLabs to accelerate adoption without building a sales and distribution infrastructure from scratch. For Agilent, it offers a path to reassert relevance in a sequencing market where short-read platforms are reaching saturation, and multi-omic workflows are emerging as the next competitive arena.
Through shared educational programs and demonstrations, the two companies aim to expand the use case portfolio for native-read targeted sequencing, while also shaping the expectations of regulators, academic consortia, and biopharma development teams about what is achievable at scale.
Wasatch BioLabs, Agilent to scale native-read targeted sequencing for precision multi-omics added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →